Wegovy and Sildenafil Interaction: What You Need to Know

How Wegovy and Sildenafil Each Affect Blood Pressure

Both drugs lower blood pressure, but through completely different pathways. Semaglutide 2.4 mg acts on GLP-1 receptors in the vasculature and kidney, promoting natriuresis and reducing sympathetic tone, while sildenafil inhibits phosphodiesterase type 5 (PDE5), preventing breakdown of cyclic GMP in vascular smooth muscle and causing direct arterial and venous dilation. The result is two agents working on two separate molecular switches, both pointing toward lower systolic pressure.

Semaglutide's Blood-Pressure Effect

In the STEP-1 trial (N=1,961), participants treated with semaglutide 2.4 mg subcutaneously once weekly experienced a mean systolic blood pressure reduction of approximately 6.2 mmHg from baseline at 68 weeks, compared with 1.4 mmHg in the placebo group [1]. A portion of that reduction traces back to the roughly 14.9% body-weight loss seen in the semaglutide arm, because adipose tissue reduction itself lowers vascular resistance. Some reduction is weight-independent: GLP-1 receptors on renal tubular cells and endothelial cells respond directly to receptor activation, independent of caloric deficit [2].

The STEP-2 trial (N=1,210, type 2 diabetes population) confirmed a mean systolic reduction of 3.9 mmHg with semaglutide 2.4 mg versus 0.5 mmHg placebo, suggesting the vasodilatory component persists even in a metabolically different population [3].

Sildenafil's Blood-Pressure Effect

Sildenafil (Viagra, Revatio) produces a mean peak reduction of 8 to 10 mmHg systolic and 5 to 6 mmHg diastolic at the 50 to 100 mg oral dose used for erectile dysfunction [4]. At the higher continuous-dosing regimens used in pulmonary arterial hypertension (Revatio 20 mg three times daily), the systolic effect accumulates differently. The FDA-approved Viagra label explicitly states that sildenafil can augment the hypotensive effects of antihypertensive agents and warns against co-administration with nitrates of any form [5].

Sildenafil's peak plasma concentration occurs 30 to 120 minutes post-dose, meaning its hemodynamic effect is time-limited. That temporal peak matters clinically: a patient who injects semaglutide on a weekly schedule maintains steady-state drug levels, creating a persistent, low-magnitude blood-pressure reduction on top of which sildenafil's acute peak is superimposed.

Pharmacokinetic Interaction: What the CYP Data Actually Show

There is no clinically meaningful pharmacokinetic interaction between semaglutide and sildenafil. Here is why.

Semaglutide's Metabolic Profile

Semaglutide is a 34-amino-acid fatty-acid-conjugated peptide. It is metabolized by ubiquitous proteolytic enzymes, not by cytochrome P450 enzymes and not by P-glycoprotein transporters. The Wegovy prescribing information does not list any CYP-based drug interactions [6]. Semaglutide does slow gastric emptying, which can theoretically delay absorption of orally administered drugs. In dedicated pharmacokinetic sub-studies within the SUSTAIN program (the subcutaneous semaglutide trials for type 2 diabetes), gastric-emptying effects were most pronounced at treatment initiation and attenuated over weeks of therapy [7].

Sildenafil's Metabolic Profile

Sildenafil is primarily metabolized by CYP3A4 and, to a lesser degree, CYP2C9. Its principal circulating metabolite, N-desmethyl sildenafil, retains roughly 50% of the PDE5 inhibitory potency of the parent compound. Co-administration with strong CYP3A4 inhibitors (ketoconazole, ritonavir) markedly increases sildenafil exposure; co-administration with CYP3A4 inducers (rifampin) reduces it [5].

Because semaglutide does not touch CYP3A4 or CYP2C9, it does not alter sildenafil's area under the curve, peak concentration, or half-life. No dose adjustment to sildenafil is pharmacokinetically warranted when Wegovy is added to a regimen.

The Gastric-Emptying Caveat

Semaglutide's slowing of gastric emptying is a real but modest pharmacokinetic variable for oral drugs. Sildenafil is already recommended to be taken on an empty stomach to maximize absorption speed and predictability, so patients taking sildenafil for erectile dysfunction are generally instructed to avoid high-fat meals before dosing anyway [5]. The incremental delay from semaglutide-induced gastroparesis is unlikely to be clinically significant for sildenafil, but it may blunt the time-to-onset of sildenafil's effect by an additional 15 to 30 minutes.

Pharmacodynamic Interaction: The Additive Hypotension Risk

This is the interaction that matters. Two agents that each lower blood pressure, combined, produce lower blood pressure than either alone. This is not a surprising pharmacological finding, but the magnitude and timing deserve attention.

Who Is at Highest Risk

Not every patient on Wegovy who takes sildenafil will develop symptomatic hypotension. The patients most likely to experience meaningful blood-pressure drops are:

• Men on one or more antihypertensive medications (angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers, calcium channel blockers, or thiazide diuretics) in addition to both study drugs
• Patients with autonomic neuropathy, common in longstanding type 2 diabetes
• Individuals who are volume-depleted from diarrhea, nausea, or vomiting associated with GLP-1 therapy initiation
• Patients at or near their blood-pressure treatment target (systolic <130 mmHg per ACC/AHA 2017 guidelines) before starting either agent

The 2017 ACC/AHA Hypertension Guideline defines stage 1 hypertension beginning at 130/80 mmHg and recommends antihypertensive drug therapy when 10-year ASCVD risk is 10% or higher [8]. A man already treated to that threshold who adds semaglutide (minus 5 to 6 mmHg systolic) and then takes sildenafil (minus 8 to 10 mmHg systolic peak) could transiently drop to a systolic range that produces dizziness or presyncope.

GLP-1 Receptor Agonists and Volume Status

GLP-1 receptor agonists promote mild natriuresis. In early weeks of therapy, before caloric restriction has stabilized, patients may experience net fluid loss from this mechanism combined with reduced oral intake. Nausea and occasional vomiting during dose escalation (weeks 1 through 16 for the standard Wegovy titration schedule) further reduce circulating volume [6]. Sildenafil taken during a period of active GLP-1-related volume depletion carries a higher hypotension risk than sildenafil taken after the patient has reached steady-state semaglutide at 2.4 mg and dietary patterns have stabilized.

Severity Classification

Major drug-interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) do not list semaglutide-sildenafil as a contraindicated combination. The interaction is typically classified as moderate, meaning the prescriber should monitor and counsel but is not required to avoid concurrent use. This contrasts with the absolute contraindication that applies to sildenafil plus any organic nitrate (nitroglycerin, isosorbide mononitrate, amyl nitrite), where combined PDE5 inhibition and nitrate-mediated cGMP accumulation can cause catastrophic, refractory hypotension [5].

The practical clinical read: Wegovy plus sildenafil is not in the same danger zone as Viagra plus nitroglycerin. Thoughtful monitoring and patient education are sufficient for most patients.

Mechanism Summary at the Molecular Level

To be precise about the biology:

Semaglutide binds the GLP-1 receptor (a G-protein-coupled receptor coupled to Gs), activating adenylyl cyclase, raising intracellular cyclic AMP, and producing downstream effects that include renal sodium excretion, mild peripheral vasodilation, and, over weeks, reduced body adiposity and sympathetic nervous system activity.

Sildenafil inhibits PDE5, the enzyme that degrades cyclic GMP in smooth muscle cells. With less PDE5 activity, cyclic GMP accumulates, activating protein kinase G, which phosphorylates myosin light-chain kinase and reduces intracellular calcium, producing smooth-muscle relaxation in arterial and venous beds.

The two pathways converge at the level of vascular smooth muscle tone but use entirely different second messengers (cAMP versus cGMP) and entirely different enzymatic machinery. They do not compete for the same receptor. They do not inhibit each other's metabolic clearance. They simply both reduce the resistance against which the heart pumps.

Clinical Monitoring Parameters

When a patient is on both Wegovy and sildenafil, monitoring should address three domains.

Blood Pressure Surveillance

Measure seated blood pressure at each clinical contact during the Wegovy dose-escalation period (months 1 through 5). After reaching the maintenance dose of 2.4 mg weekly, blood-pressure checks every 3 months are reasonable for patients also using sildenafil, or more frequently if antihypertensives are part of the regimen. Target the ACC/AHA goal of <130/80 mmHg in most adults, but watch for over-treatment: sustained readings below 110/70 mmHg in a symptomatic patient warrant antihypertensive de-escalation before attributing hypotension to sildenafil alone.

Symptom Monitoring

Instruct patients to report dizziness, lightheadedness, or near-fainting, particularly in the 1 to 2 hours after sildenafil dosing (the peak-effect window). Syncope after sildenafil is rare in healthy men but is well-documented in those with co-existing antihypertensive therapy [5]. Patients should also be counseled that hot environments, alcohol, and prolonged standing amplify sildenafil's vasodilatory effect, compounding any background pressure reduction from semaglutide.

Medication Reconciliation

Before prescribing Wegovy to a patient already on sildenafil, review the full antihypertensive regimen. The combination of semaglutide plus sildenafil plus a calcium channel blocker, for example, represents three concurrent blood-pressure-lowering inputs. The prescriber may need to reduce the antihypertensive dose prophylactically, particularly if the patient's blood pressure at initiation is already at goal.

Dose Adjustment Guidance

No pharmacokinetic dose adjustment is required for either drug. The FDA prescribing information for Wegovy does not list sildenafil under drug interactions, and the Viagra label does not list semaglutide [5][6].

For practical management:

• Sildenafil dose for erectile dysfunction (25 mg, 50 mg, or 100 mg as needed): start at the lowest effective dose (25 mg) in patients on Wegovy who are also taking antihypertensives. The 50 mg starting dose recommended in the general population may be too large a hemodynamic step for someone already at a lower baseline pressure.
• Sildenafil for pulmonary arterial hypertension (Revatio 20 mg three times daily): the continuous-dosing regimen produces a smaller per-dose hemodynamic peak but a sustained trough effect. Blood-pressure monitoring every 1 to 2 weeks during the first month of concurrent use is appropriate.
• Wegovy titration schedule: the standard schedule escalates from 0.25 mg weekly (weeks 1 to 4) to 0.5 mg (weeks 5 to 8), 1.0 mg (weeks 9 to 12), 1.7 mg (weeks 13 to 16), then 2.4 mg maintenance. The highest hypotension risk coincides with dose escalation steps, not maintenance.

Patient Counseling Points

Clear, specific communication reduces the risk of adverse events more reliably than any dose adjustment.

Patients should understand these five things before combining the two drugs:

1. Wegovy gradually lowers blood pressure over weeks and months as weight falls and GLP-1 effects accumulate.
2. Sildenafil lowers blood pressure acutely, peaking about 1 hour after the dose and resolving within 4 to 6 hours.
3. Combining them is not dangerous in the way that combining sildenafil with nitrates is dangerous, but dizziness is a real possibility, especially early in Wegovy therapy.
4. Standing up slowly after taking sildenafil, avoiding alcohol on dosing days, and staying hydrated reduce the risk of orthostatic symptoms.
5. Any episode of syncope or near-syncope after sildenafil warrants same-day medical evaluation, not just a note for the next appointment.

The American Urological Association's 2018 Erectile Dysfunction Guideline states: "Clinicians should discuss with patients the cardiovascular risks, including hypotension, associated with PDE5 inhibitors, particularly in those taking antihypertensive medications" [9]. That guidance extends directly to patients on GLP-1 receptor agonists that exert independent antihypertensive effects.

Special Populations

Men With Obesity and Erectile Dysfunction

This is actually the most common clinical scenario for this combination. Erectile dysfunction (ED) is highly prevalent in men with obesity: a cross-sectional analysis of 2,126 men in the Massachusetts Male Aging Study found that ED prevalence rose from 25% in normal-weight men to 43% in obese men [10]. Many of the men prescribed Wegovy for weight management will have pre-existing ED and may be current or future sildenafil users. The prescriber should anticipate this overlap and address both drugs in the initial Wegovy intake visit rather than waiting for the patient to raise it.

Weight loss itself may improve erectile function independent of sildenafil: a 2011 RCT published in the Journal of Sexual Medicine (N=110) found that a two-year lifestyle intervention producing 10% weight loss significantly improved IIEF scores compared with control [11]. Semaglutide-induced weight loss may therefore reduce the sildenafil dose needed over time, which incidentally reduces the additive hypotension exposure.

Men With Type 2 Diabetes

The STEP-2 trial enrolled men and women with type 2 diabetes and overweight or obesity. Men with diabetes have higher rates of autonomic neuropathy, which blunts baroreceptor reflexes and makes orthostatic hypotension more likely when any vasodilatory drug is added. In this subgroup, the combination of semaglutide, sildenafil, and an antihypertensive (common in type 2 diabetes management) warrants the most careful blood-pressure monitoring [3].

Patients Using Sildenafil for Pulmonary Arterial Hypertension

This is a distinct clinical population. Pulmonary arterial hypertension (PAH) patients use Revatio (sildenafil 20 mg three times daily) to reduce pulmonary vascular resistance. If such a patient develops obesity-related comorbidities and is considered for Wegovy, the prescriber should consult with the patient's pulmonologist before starting. Systemic blood-pressure effects in PAH patients on sildenafil may be more pronounced, and the margin for additional antihypertensive load is narrower.

What the FDA Labels Say

The Wegovy (semaglutide injection 2.4 mg) prescribing information approved by the FDA in June 2021 does not list sildenafil under section 7 (Drug Interactions). It does note that semaglutide delays gastric emptying and may affect absorption of concomitant oral medications, with advice to monitor drugs with narrow therapeutic windows [6].

The Viagra (sildenafil citrate) prescribing information identifies two interaction categories with hemodynamic relevance: organic nitrates (absolutely contraindicated) and antihypertensive agents (additive effect, use with caution) [5]. GLP-1 receptor agonists are not listed as a named class in the Viagra label, though the mechanism that applies to antihypertensives applies equally here by pharmacological extension.

The absence of a named interaction in both labels reflects the timeline: regulatory labels are updated based on post-market pharmacovigilance and sponsor-submitted PK studies, and a formal semaglutide-sildenafil DDI study has not been published in the peer-reviewed literature as of this writing.